Dynamics of natural product Lupenone as a potential fusion inhibitor against the spike complex of novel Semliki Forest Virus.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2022
2022
Historique:
received:
03
11
2021
accepted:
27
01
2022
entrez:
25
2
2022
pubmed:
26
2
2022
medline:
11
3
2022
Statut:
epublish
Résumé
The Semliki Forest Virus (SFV) is an RNA virus with a positive-strand that belongs to the Togaviridae family's Alphavirus genus. An epidemic was observed among French troops stationed in the Central African Republic, most likely caused by the SFV virus. The two transmembrane proteins El and E2 and the peripheral protein E3 make up the viral spike protein. The virus binds to the host cell and is internalized via endocytosis; endosome acidification causes the E1/E2 heterodimer to dissociate and the E1 subunits to trimerize. Lupenone was evaluated against the E1 spike protein of SFV in this study based on state-of-the-art cheminformatics approaches, including molecular docking, molecular dynamics simulation, and binding free energy calculation. The molecular docking study envisaged major interactions of Lupenone with binding cavity residues involved non-bonded van der Waal's and Pi-alkyl interactions. Molecular dynamic simulation of a time scale 200 ns corroborated interaction pattern with molecular docking studies between Lupenone and E1 spike protein. Nevertheless, Lupenone intearcation with the E1 spike protein conforming into a stable complex substantiated by free energy landscape (FEL), PCA analysis. Free energy decomposition of the binding cavity resdiues of E1 spike protein also ensured the efficient non-bonded van der Waal's interaction contributing most energy to interact with the Lupenone. Therefore, Lupenone interacted strongly at the active site conforming into higher structural stability throughout the dynamic evolution of the complex. Thus, this study perhaps comprehend the efficiency of Lupenone as lead molecule against SFV E1 spike protein for future therapeutic purpose.
Identifiants
pubmed: 35213606
doi: 10.1371/journal.pone.0263853
pii: PONE-D-21-34962
pmc: PMC8880844
doi:
Substances chimiques
Triterpenes
0
Viral Fusion Proteins
0
lupenone
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0263853Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
J Cell Biol. 1996 Aug;134(4):863-72
pubmed: 8769412
J Virol. 1993 Dec;67(12):7597-607
pubmed: 8230478
J Virol. 1995 Apr;69(4):2471-9
pubmed: 7884895
J Gen Virol. 1987 Aug;68 ( Pt 8):2129-42
pubmed: 2886548
Am J Trop Med Hyg. 1990 Apr;42(4):386-93
pubmed: 2158754
J Virol. 1994 Nov;68(11):6940-6
pubmed: 7933075
J Virol. 1992 Dec;66(12):7309-18
pubmed: 1433520
J Chem Theory Comput. 2010 May 11;6(5):1509-19
pubmed: 26615687
J Cell Biol. 1980 Oct;87(1):264-72
pubmed: 7419594
Virology. 1990 Mar;175(1):110-23
pubmed: 2155505
Proc Natl Acad Sci U S A. 1988 Aug;85(16):5997-6001
pubmed: 3413072
Biomed Pharmacother. 2018 Jul;103:198-203
pubmed: 29653365
Structure. 2006 Jan;14(1):75-86
pubmed: 16407067
Comput Biol Chem. 2020 Jun 24;87:107322
pubmed: 32604028
Int J Mol Sci. 2019 Jan 08;20(1):
pubmed: 30626119
J Enzyme Inhib Med Chem. 2009 Aug;24(4):1056-9
pubmed: 19548777
Nature. 1980 Nov 20;288(5788):236-41
pubmed: 6985476
Science. 1979 Mar 16;203(4385):1127-9
pubmed: 424742
Virology. 1983 Aug;129(1):170-87
pubmed: 6310876
Nat Prod Res. 2003 Oct;17(5):375-80
pubmed: 14526920
J Mol Biol. 1978 Jul 5;122(3):259-69
pubmed: 691044
Proc Natl Acad Sci U S A. 1980 Jun;77(6):3273-7
pubmed: 6997876
J Virol. 1991 Aug;65(8):4292-300
pubmed: 2072453
Virology. 1986 Jul 30;152(2):400-13
pubmed: 3088830
J Gen Virol. 1985 Mar;66 ( Pt 3):395-408
pubmed: 2982998
J Virol. 1990 Mar;64(3):1233-40
pubmed: 2304141
J Cheminform. 2011 Oct 07;3:33
pubmed: 21982300
Proc Natl Acad Sci U S A. 1981 Apr;78(4):2062-6
pubmed: 6941270